Eye injection medicine after repeat retinal detachment surgery
Part of Eyes & vision clinical trials.
This Phase 2 trial tests an injection of topotecan into the eye after surgery for retinal detachment that keeps coming back due to scar tissue (proliferative vitreoretinopathy). It may help improve how the retina heals after difficult, repeat operations when vision is usually very guarded.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You had repeat retinal detachment surgery (vitrectomy and/or scleral buckle) in the same eye because the detachment came back due to scar tissue (PVR).
- Your retinal detachment is graded as PVR C or D (more severe scarring stages).
- You have already had at least one retinal detachment surgery in that same eye before, and there is documentation that the retina detached again after that surgery.
- You are able and willing to follow the study plan (go to visits, follow instructions).
- If you plan to have cataract surgery at the same time as the detachment surgery, you may still be eligible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at imaging and blood-based markers to better understand retinal detachment. It aims to find ways to predict how well the retina might reattach after surgery.
This study tests whether an injection of a drug called topotecan, given during or right after eye surgery for retinal detachment, can help prevent or treat a condition called proliferative vitreoretinopathy (PVR) that can cause the retina to detach again. If you're having surgery for a retinal detachment, this trial might help reduce the risk of needing more surgeries.
This trial tests an experimental drug called topotecan, given as an injection directly into the eye during surgery, to see if it safely helps prevent scar tissue from pulling the retina out of place again. It is for people having surgery for retinal detachment with severe scarring or injury.
This trial tests whether giving bevacizumab (a medicine that slows abnormal blood vessel growth) right after vitrectomy (a surgery to remove blood or scar tissue from the eye) can help people with advanced diabetic eye disease. The goal is to improve vision and reduce the need for more treatments.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
Hear when a new Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.